NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/31/2026
Back to search
Official data from USPTO
CAPSIDA BIOTHERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CAPSIDA BIOTHERAPEUTICS
ST13
US500000090046614Class
1, 5, 42
Filing
90046614
Registration
8196323
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
63
Latest update
03/31/2026
Trademark type
Word
Nice classes
1, 5, 42
Filing date
07/10/2020
Registration date
03/31/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/31/2026
Last transaction
03/31/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
07/05/2024
First use in commerce
07/05/2024
Drawing code
4
Owner type
03
Owner location
Thousand Oaks, CA, US
Examiner
LAPTER, ALAIN J
Law office
L50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
CAPSIDA BIOTHERAPEUTICS, INC.
Capsida, Inc.
Representatives
Holly Pranger PRANGER LAW PC
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical and biochemical products for use in gene delivery technologynucleic acidsincluding coding and non-coding deoxyribonucleic acidsplasmidsvectorspromotorsenhancers and other regulatory sequences; Chemical and biochemical products for use in gene delivery technology namelynucleic acidsincluding coding and non-coding deoxyribonucleic acidsvectorspromotorsenhancers and other regulatory sequences for development of therapeutics and the treatment of cardiovascularcentral nervous systemneurologicalperipheral nervous system diseases and disorders; Chemical and biochemical products for use in gene delivery technology namelynucleic acidsincluding plasmids for development of therapeutics and the treatment of central nervous systemneurologicalperipheral nervous system diseases and disorders
Class 5
Pharmaceutical preparations for use in gene therapy; pharmaceutical preparations for use in gene delivery technology for use in the treatment of central nervous systemneurologicalperipheral nervous system diseases and disorders; pharmaceutical preparations for use in the treatment of gene therapy treatable diseases for use in the treatment of central nervous systemneurologicalperipheral nervous system diseases and disorders; gene therapy and prophylaxis productsgene transferregulationmodulation and delivery pharmaceutical preparations for the treatment of genetic diseases and disorders; pharmaceutical preparations for the treatment of disorders of the central nervous system; pharmaceutical preparations that facilitate administration of other pharmaceutical preparations into the brain for enhanced treatment of disorders of the central nervous systemin the nature of drug delivery agents consisting of viral capsids that facilitate the delivery of the preparations; pre-filled vials containing pharmaceutical preparations for the treatment of central nervous systemneurologicalperipheral nervous system diseases and disorders and complications associated therewith
Class 42
Pharmaceutical research and development in the field of gene therapy; development of pharmaceutical preparations for use in gene therapy and gene delivery technology; development of products being genetic therapies; scientific research in the field of genetic engineeringbiotechnology research servicesresearch and development of new products in the field of gene therapeutics and research tools; research and development in the biotechnology field; scientific and medical research and development in the field of cardiovascularcentral nervous systemneurologicalophthalmologicperipheral nervous system diseases and disorders and complications associated therewith; scientific research and product development services for others in the pharmaceuticalbiotechnologymedical fields; testinginspectionresearchdevelopment of pharmaceutical preparations for gene therapy and gene delivery technology; biomedical research and developmentscientific research and developmentpharmaceutical research and development and product development services in the fields of genome editinggene editinggenome engineeringgene modulationgenetic diseasesgene therapycell therapy; product development in the fields of genetic therapiesgene delivery technologieseffectors to regulatemodulatecharacterize disease states; biomedical research in the field of gene therapy design and delivery; gene therapy design and product delivery development of biochemical assays; biomedical research and developmentscientific research and developmentpharmaceutical research and development and product development in the fields of cardiovascularcentral nervous systemneurologicalophthalmologicperipheral nervous system diseases and disorders; medical servicesscientific research in the fields of genetic engineering and gene therapy services; medical servicesscientific research in the nature of gene therapy design and delivery services in the field of genetic diseases and disorders
Publications
History of USPTO decisions and trademark events.
63 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
03/31/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
03/10/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/10/2026
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/07/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/06/2026
EX5G
SOU EXTENSION 5 GRANTED
03/06/2026
IUAF
USE AMENDMENT FILED
10/03/2025
EXT5
SOU EXTENSION 5 FILED
10/03/2025
EISU
TEAS STATEMENT OF USE RECEIVED
10/03/2025
EEXT
SOU TEAS EXTENSION RECEIVED
10/03/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/29/2025
EX4G
SOU EXTENSION 4 GRANTED
03/29/2025
EXT4
SOU EXTENSION 4 FILED
03/28/2025
EEXT
SOU TEAS EXTENSION RECEIVED
03/28/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/01/2024
EX3G
SOU EXTENSION 3 GRANTED
10/01/2024
EXT3
SOU EXTENSION 3 FILED
10/01/2024
EEXT
SOU TEAS EXTENSION RECEIVED
10/01/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/05/2024
EX2G
SOU EXTENSION 2 GRANTED
03/04/2024
EXT2
SOU EXTENSION 2 FILED
03/04/2024
EEXT
SOU TEAS EXTENSION RECEIVED
03/04/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/29/2023
EX1G
SOU EXTENSION 1 GRANTED
09/27/2023
EXT1
SOU EXTENSION 1 FILED
09/27/2023
EEXT
SOU TEAS EXTENSION RECEIVED
09/27/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/04/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/07/2023
PUBO
PUBLISHED FOR OPPOSITION
02/07/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/18/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/05/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/21/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/21/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/21/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/23/2022
GNRT
NON-FINAL ACTION E-MAILED
06/23/2022
CNRT
NON-FINAL ACTION WRITTEN
06/23/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
06/21/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/16/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/16/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/16/2022
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
12/01/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
06/01/2021
GNSL
LETTER OF SUSPENSION E-MAILED
06/01/2021
CNSL
SUSPENSION LETTER WRITTEN
06/01/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
06/01/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/01/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
06/01/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/28/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/27/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/27/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/04/2020
GNRT
NON-FINAL ACTION E-MAILED
12/04/2020
CNRT
NON-FINAL ACTION WRITTEN
12/04/2020
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
11/04/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/24/2020
GNRT
NON-FINAL ACTION E-MAILED
10/24/2020
CNRT
NON-FINAL ACTION WRITTEN
10/24/2020
DOCK
ASSIGNED TO EXAMINER
10/21/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/06/2020
NWAP
NEW APPLICATION ENTERED
07/14/2020
Continuous trademark protection
Get notified about every new filing that threatens CAPSIDA BIOTHERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.